Fund profile by ISIN IE00BYXG2H39
iShares Nasdaq US Biotechnology UCITS ETF
Research iShares Nasdaq US Biotechnology UCITS ETF by ISIN IE00BYXG2H39: TER 0.35%, domicile Ireland, accumulating, and 1-year price performance +54.9%.
ISINIE00BYXG2H39
TER0.35%
DomicileIreland
Distribution policyAccumulating
Index—
Fund size1.1B
Holdings—
1-year price performance+54.9%
Exchange listings and tradability
| Ticker | Exchange | Currency | Country | Avg daily turnover | Avg daily shares |
|---|---|---|---|---|---|
| 2B70.DE | XETRADefault at German brokers | EUR | Ireland | €1.8M | 220,976 |
| BTEC.L | LSE | USD | Ireland | €864K | 106,957 |
| BTEC.SW | SW | USD | Ireland | €568K | 68,000 |
| BTEK.L | LSE | GBP | Ireland | €382K | 47,111 |
Avg daily turnover is the 90-day average, converted to euros so venues in different currencies can be compared; avg daily shares is the same window in units. The most traded listing is shown first. This fund trades on a German exchange. As of 2026-08-28.
Largest holdings
The 10 largest holdings make up 40.76% of the fund. As of 2026-08-11.
| Holding | Symbol | Weight |
|---|---|---|
| Vertex Pharmaceuticals Inc | VRTX | 8.13% |
| Amgen Inc | AMGN | 7.87% |
| Gilead Sciences Inc | GILD | 6.88% |
| Regeneron Pharmaceuticals Inc | REGN | 4.49% |
| Alnylam Pharmaceuticals Inc | ALNY | 2.81% |
| Revolution Medicines Inc Ordinary Shares | RVMD | 2.78% |
| Biogen Inc | BIIB | 2.23% |
| Moderna Inc | MRNA | 1.94% |
| Illumina Inc | ILMN | 1.86% |
| argenx SE ADR | ARGX | 1.79% |
Performance is the historical price return of the representative listing. Distributions are excluded and past performance is not a forecast.